FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation

Jun Yan; Qingnan Zhao; Konrad Gabrusiewicz; Ling-Yuan Kong; Xueqing Xia; Jian Wang; Martina Ott; Jingda Xu; R. Eric Davis; Longfei Huo; Ganesh Rao; Shao-Cong Sun; Stephanie S. Watowich; Amy B. Heimberger; Shulin Li

doi:10.1038/s41467-018-08271-x

Nature Communications (Jan 2019)

FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation

Jun Yan,
Qingnan Zhao,
Konrad Gabrusiewicz,
Ling-Yuan Kong,
Xueqing Xia,
Jian Wang,
Martina Ott,
Jingda Xu,
R. Eric Davis,
Longfei Huo,
Ganesh Rao,
Shao-Cong Sun,
Stephanie S. Watowich,
Amy B. Heimberger,
Shulin Li

Affiliations

Jun Yan: Center for Brain Disorders Research, Capital Medical University
Qingnan Zhao: Department of Pediatrics–Research, The University of Texas MD Anderson Cancer Center
Konrad Gabrusiewicz: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center
Ling-Yuan Kong: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center
Xueqing Xia: Department of Pediatrics–Research, The University of Texas MD Anderson Cancer Center
Jian Wang: Department of Biostatistics, The University of Texas MD Anderson Cancer Center
Martina Ott: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center
Jingda Xu: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center
R. Eric Davis: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center
Longfei Huo: Department of Pediatrics–Research, The University of Texas MD Anderson Cancer Center
Ganesh Rao: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center
Shao-Cong Sun: Department of Immunology, The University of Texas MD Anderson Cancer Center
Stephanie S. Watowich: Department of Immunology, The University of Texas MD Anderson Cancer Center
Amy B. Heimberger: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center
Shulin Li: Department of Pediatrics–Research, The University of Texas MD Anderson Cancer Center

DOI: https://doi.org/10.1038/s41467-018-08271-x
Journal volume & issue: Vol. 10, no. 1
pp. 1 – 15

Abstract

Read online

Fibrinogen-like protein 2 (FGL2) mediates immune suppression in glioblastoma (GBM). Here, the authors show that FGL-2 expressed by GBM cancer cells acts by suppressing the differentiation of CD103+ DC cells required to activate the anti-tumor CD8+ T cell response via blocking GM-CSF signalling at NFKB, STAT1/5 and p38 level.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal